David Meeker, Rhythm Pharmaceuticals CEO
December 22, 2020 10:17 AM ESTUpdated 10:57 AM
R&D

Rhythm Phar­ma knocked off stride as mixed PhI­II obe­si­ty da­ta for its sole big drug look ‘meh’ to many

John Carroll

Editor & Founder

Just a few weeks af­ter Rhythm Phar­ma­ceu­ti­cals $RYTM snagged an FDA OK for set­melan­otide in 3 rare ge­net­ic dis­or­ders that trig­ger obe­si­ty, the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times